

If you experience difficulty viewing this message, you can view it online [here](#).



June 2013

FerriScan Update

Resonance Health has made good progress in FerriScan sales in the first half of 2013. First quarter FerriScan sales increased significantly in the UK and USA, with growth in volumes of 18% over the same quarter in 2012.

The Company has signed two new multi-year contracts so far this year to provide FerriScan service in new clinical trials, one for the pharmaceutical industry and the other funded by the European Union to evaluate an iron chelation therapy in pediatric patients. These contracts continue to consolidate FerriScan's position as an essential tool in the development of new iron chelation therapies and will enable many new MRI centres to become familiar with FerriScan.

FerriScan is being included in more Clinical Practice Guidelines, the latest issued by the prestigious Cancer Institute in Washington State.

Since its establishment, Resonance Health has completed nearly 19,000 FerriScan measurements, providing a valuable service to the international health care community. Access to FerriScan has recently been expanded to new customers in Switzerland, Italy and Tunisia.

Further FDA Authorisation for FerriScan

FerriScan received FDA authorisation for marketing as an **imaging companion diagnostic** to Exjade (Deferoxamine) for the treatment of Non-Transfusion Dependent Thalassaemia (NTDT) patients in the USA. The FDA's media release stated: *"The FerriScan device is a non-invasive test that helps physicians to select appropriate patients for Exjade therapy as well as monitor their response to the drug, and discontinue therapy when LIC reaches safe levels."* Click [here](#) for further information

Resonance Health is working to expand the availability of FerriScan at MRI centres across the USA for this new indication.

FerriScan was listed in the 2013 World Health Organisation Report on "Regulatory Action and News". This recognition for FerriScan by the WHO as a regulatory authority approved companion diagnostic to Exjade further supports its value in the global market as "the gold standard" in the non-invasive measure of liver iron concentration. The WHO information is available [here](#).

Research and Development Tax Incentive Received

Resonance Health is pleased to report that it has received a cash payment under the Australian Federal Government's Research and Development Tax Incentive Program of \$188k for the 2011-2012 year. The legislation provides annual cash refunds of 45% on qualifying R&D expenditure benefiting organisations such as Resonance Health.

Export Market Development Grant Received

FerriScan Reimbursement in the US

Medical Mutual of Ohio, USA has issued a positive coverage policy for FerriScan, determining that FerriScan is medically necessary and eligible for reimbursement for patients across a range of indications. This follows positive coverage policies for FerriScan issued by two other health insurance payers in 2012. To assist our reimbursement efforts Resonance Health is also collaborating with two key opinion leaders in the US in researching and publishing data that will demonstrate the positive impact of FerriScan on patient health outcomes.

Liver Fibrosis

Resonance Health is continuing its research into the assessment of fibrosis using MRI. Further analysis of the data obtained in the recent fibrosis study is being undertaken in collaboration with researchers at the University of Western Australia with expertise in image processing with the aim to discriminate between lower and higher grades of liver fibrosis.

Email

If you would like any further information please email Resonance Health at info@resonancehealth.com

Resonance Health (RHT)
Head Office 278 Stirling Highway,
Claremont, Western Australia 6010
Postal Address PO Box 1135,
Nedlands, Western Australia 6909
P: +61 (0)8 9286 5300 F: +61 (0)8
9286 1179
W: www.resonancehealth.com

Resonance Health is also pleased to report that it has received the first cash payment of \$60k under the Australian Federal Government's Export Market Development Grant (EMDG) for the 2011-2012 year. The EMDG provides a reimbursement of a proportion of eligible expenditure associated with export promotion activities including overseas representatives. Over 90% of the Company's revenue is received from export markets. An additional cash receipt under this program is expected in late June depending on funds available within the program.

HepaFat-Scan Update

Resonance Health is continuing its communication with the FDA as the Company progresses its application for US marketing clearance of HepaFat-Scan. The FDA requested additional information on the HepaFat-Scan 510k submission which was provided in March. Further information has recently been requested which is currently being collated for submission.

[Click to invite a friend to receive our eNewsletter](#)

[Click to unsubscribe](#)

www.eNewslettersOnline.com